Linker Information

General Information of This Linker
Linker ID
LIN0HHPZM
Linker Name
Maleimido-caproyl-PEG8-Val-Ala-PABC
Antibody-Linker Relation
Cleavable
Structure
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
Plozalizumab plevistinag [Phase 1/2 (discontinued)]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Eligible participants (ECOG 0-1) have advanced solid tumors (e.g., NSCLC, pancreatic adenocarcinoma, RCC) refractory to prior therapies, with specific requirements per cohort (e.g., 2L NSCLC: anti-PD- (L)1 progression; 3L RCC: prior VEGFR TKI + immunotherapy). Key exclusions: cardiac/pulmonary dysfunction (NYHA III-IV, pneumonitis), uncontrolled hepatitis, recent immunosuppressants/radiotherapy, or hypersensitivity to study drugs. Lab thresholds include ANC ≥1000/uL, creatinine clearance ≥30 mL/min, and LVEF >50%. HCC requires Child-Pugh ≤7.

   Click to Show/Hide
Related Clinical Trial
NCT Number NCT05070247  Clinical Status PHASE1|||PHASE2
Clinical Description
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors

   Click to Show/Hide
Primary Endpoint
The study evaluates safety endpoints including Grade ≥3 TEAEs, SAEs, DLTs (Cycle 1, per NCI CTCAE v5.0), and treatment modifications/discontinuations over ~50 months. Efficacy in dose expansion focuses on ORR (confirmed PR/CR per RECIST 1.1), DCR (CR+PR+SD >6 weeks), DOR, TTR, PFS, and OS, with RECIST-defined tumor assessments.
Other Endpoint
Pharmacokinetics of TAK-500 (single/multi-dose) include Cmax, Tmax, AUCt, AUCinf, t1/2, CL, and Vss, measured during Cycles 1-4. Biomarkers assess intratumoral immune cell changes (IHC/ISH) and ADA immunogenicity. Tumor response metrics (ORR/DCR/DOR/TTR in escalation/expansion) follow RECIST 1.1, while survival endpoints (PFS/OS) track progression/death over ~50 months.

   Click to Show/Hide
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT04879849  Clinical Status Phase 1
Clinical Description
An open-label, phase 1, dose-escalation study to evaluate the safety and preliminary antitumor activity of TAK-676 with pembrolizumab following radiation therapy in the treatment of non-small-cell lung cancer, triple-negative breast cancer, or squamous-cell carcinoma of the head and neck that has progressed on checkpoint inhibitors.
Experiment 3 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT04420884  Clinical Status Phase 1
Clinical Description
An open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-676 as a single agent and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.
References
Ref 1 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Ref 2 An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 With Pembrolizumab Following Radiation Therapy in the Treatment of Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck That Has Progressed on Checkpoint Inhibitors
Ref 3 An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors